Edition:
United States

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

7.81USD
4:00pm EDT
Change (% chg)

$-0.25 (-3.10%)
Prev Close
$8.06
Open
$8.10
Day's High
$8.10
Day's Low
$7.69
Volume
17,325
Avg. Vol
44,654
52-wk High
$17.33
52-wk Low
$6.65

Chart for

About

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on... (more)

Overall

Beta: --
Market Cap(Mil.): $328.81
Shares Outstanding(Mil.): 40.80
Dividend: --
Yield (%): --

Financials

  MCRB.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -2.26 -- --
ROI: -63.86 2.89 12.63
ROE: -245.32 1.65 14.82

BRIEF-Seres Therapeutics Reports Qtrly Loss Per Share Of $0.69

* SERES THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES

May 09 2018

BRIEF-Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc

* Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc As Of April 10, 2018 - SEC Filing Source text (https://bit.ly/2GSzKlq) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 11 2018

Seres Therapeutics wins dismissal of investor lawsuit over drug study

Biopharmaceutical company Seres Therapeutics Inc has won the dismissal of a lawsuit claiming it misled investors about the potential of an oral microbiome therapeutic drug that it was developing.

Apr 02 2018

BRIEF-Seres Therapeutics Qtrly Net Loss Of $29.0 Mln Vs $25.3 Mln

* SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

Mar 08 2018

Earnings vs. Estimates